作者
Xu Liu,Yukui Zhang,Jun Ma,Ning Zhang,Guan-Qun Zhou,Guorong Zou,Jun Ma,Jun Ma,Yukui Zhang,Guan-Qun Zhou,Zhen‐Yu He,Guan-Qun Zhou,Guan-Qun Zhou,Haijun Wu,Guan-Qun Zhou,Guan-Qun Zhou,Yan-Ping Mao,Jun Ma,Guan-Qun Zhou,Jing Huang,Shaoqiang Liang,Wei-Li Wu,Shu-Bin Hong,Ling Li,Ping Ai,Yanhong He,Jian Zang,Lei Chen,Guan-Qun Zhou,Guan-Qun Zhou,Cheng Xu,Jia-Wei Lv,Guan-Qun Zhou,Shu-Bin Hong,Yusheng Jie,Guan-Qun Zhou,Sai-Wei Huang,Ye‐Lin Liang,Yaqin Wang,Guan-Qun Zhou,Jinhan Zhu,Jun Ma,Song-Ran Liu,Qingguang Lin,Guan-Qun Zhou,Jun Ma,Guan-Qun Zhou,Guan-Qun Zhou,Aihua Lin,Guan-Qun Zhou,Guan-Qun Zhou,Guan-Qun Zhou,Guan-Qun Zhou,Jun Ma,Jun Ma
摘要
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population.